The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers

Abstract

Background: Inhaled medications form the foundation of pharmacologic treatment for chronic obstructive pulmonary disease (COPD).The Delivery Makes a Difference (DMaD) project was conducted to better understand health care provider (HCP) and patient perspectives about the role of inhalation delivery devices in COPD, and to examine the nature of educational efforts between HCPs and patients on proper device technique.

Methods: Data were derived from 2 original quantitative, web-based, descriptive, cross-sectional surveys distributed to HCPs who manage COPD (n=513) and patients with COPD (n=499) in the United States. Descriptive statistics were used to assess data across important demographic variables. Inferential statistics were used to assess differences in attitudinal, descriptive, and behavioral measures that were cross-tabulated with demographic data.

Results: When prescribing medication for newly diagnosed patients with stable or unstable COPD, only 37% of HCPs considered type of device to be highly important, with only 45% of HCPs assessing device technique in every newly diagnosed patient. Patients with COPD were also relatively unconcerned with proper device technique (64% never concerned), regardless of their COPD severity. Although patients did not identify education as a significant impediment to proper device use, they reported inconsistent educational experiences.

Conclusions: We found that HCPs and patients prioritize medication over device when selecting treatments, showing limited concerns about proper device use. These results highlight the need to coordinate professional education with patient-directed educational efforts to further promote proper device selection and use in COPD management.

Introduction

Supplemental Material

This article contains supplemental material.

Inhaled medications form the foundation of pharmacologic treatment for chronic obstructive pulmonary disease (COPD).¹ Inhaled delivery enables targeting medication to the airways, enabling a rapid effect with a relatively low dose of medication, thus lowering the potential for systemic bioavailability.² Several inhalation device types are available, including metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), soft mist inhalers (SMIs), and small volume nebulizers (SVNs). Each of these devices has unique attributes to consider when selecting treatment for a specific patient (Table 1).^2-5 Patient-specific factors, such as COPD severity, comorbidities, and cognitive function may affect the patient’s ability to use a particular device,⁵ as may patient perceptions of medication efficacy and device convenience, ease of use, and cost.^4,6 Insurance providers and pharmacy formularies are also factors in device selection decisions.⁶

After device selection, initial training and follow-up assessment of technique are imperative,⁷ as poor inhaler technique has been cited as a major reason for the ineffective management of COPD^2,5,8 A 2011 study by Melani et al demonstrated that the incidence of critical mistakes in device use among patients with COPD and/or asthma ranged from 12% to 44% depending on device, and that misuse was associated with an increased risk of hospitalization, emergency department visits, and poor disease control.⁸ Similarly, data from Loh and colleagues showed that suboptimal peak inspiratory flow, which is associated with the misuse of DPIs, increased the risk for 90-day COPD-related and all-cause hospital readmissions.⁹ Critical errors when using MDIs or DPIs are especially frequent in the primary care setting and among elderly patients (i.e., ≥ 65 years).¹⁰ Sulaiman and colleagues demonstrated that mean inhaler adherence, assessed as time of use, interval between doses and proper technique, was only 22.6% in a group of 244 patients (mean age, 71 years) with COPD recently discharged from the hospital.¹¹ Inhaler technique improvement and training have been shown to benefit COPD outcomes.¹² Indeed, the 2017 Global Initiative for Chronic Obstructive Lung Disease emphasizes the importance of regular inhaler technique assessment by health care providers (HCPs).¹ Despite these recommendations, many HCPs lack the awareness, knowledge, and training needed to instruct their patients on proper inhaler use.^13,14

We conducted the Delivery Makes a Difference, or DMaD, study to better understand HCP and patient perspectives about the role of inhalation delivery devices in COPD. We sought to quantify HCP and patient knowledge, attitudes, beliefs, and behaviors about inhalation devices, and to examine the nature of educational efforts between HCPs and patients on proper device technique.

Materials and Methods

Study Design

The study included 2 quantitative, web-based, descriptive, cross-sectional surveys: 1 targeting HCPs and another targeting patients with COPD in the United States. A random sample of HCPs was chosen from a proprietary American College of Chest Physicians database of pulmonologists (PUDs), respiratory care practitioners, physician assistants, and nurse practitioners. A nonprobability sample of primary care physicians (PCPs) and physician assistants was obtained using a syndicated opt-in research panel of HCPs. Patients were randomly chosen from a panel of individuals with self-identified COPD.

Health care providers who did not self-identify as a PUD, family practitioner, general internal medicine practitioner, nurse practitioner, physician assistant, or respiratory care practitioner on an initial survey screening question were excluded from participating in the survey. Physician assistants and nurse practitioners were excluded if they did not indicate practicing in a primary care or pulmonology setting. Patients were excluded if they did not indicate a diagnosis of chronic bronchitis, emphysema, or COPD upon screening. To account for survey respondents who may have filled out the survey without reading the questions, time for survey completion was monitored for each participant, and surveys with completion times that were considerably shorter than the mean were excluded from the analysis. Details of the design, content, and response rate calculations for both surveys are in the online data supplement ^{(306.2KB, pdf)} .

Sample Size and Data Analyses

A total of 513 survey responses were collected from HCPs (40.8% were PUDs, 29.2% PCPs), and 30% non-physician providers (NPPs) (physician assistants, respiratory care practitioners, and nurse practitioners). A total of 505 survey responses were collected from patients. Our sample size provided a margin of error of ±4.4% for both surveys. Descriptive statistics were used to assess data distributions across important demographic variables. Inferential statistics were used to assess differences in attitudinal, descriptive, and behavioral measures, which were cross-tabulated with demographic data. Data were analyzed using StatPac Software version 16 (Bloomington, Minnesota). Depending on data type, a 2-tailed independent samples t-test, a chi-square test, or a one-way analysis of variance was used to test for statistical significance (p<0.05). Post hoc multiple comparisons used a Bonferroni adjustment to control the family-wise error rate. Two validated scales were used in the surveys: The Medication Adherence Report Scale (MARS-5)¹⁵ for patient adherence (α=0.88) and the modified Medical Research Council Dyspnea Scale (mMRC),¹⁶ a global measure of COPD symptom severity (see the online supplement ^{(306.2KB, pdf)} ).

Results

Respondent Demographics

The HCP survey was completed by 513 HCPs (n=209 PUDs, n=150 PCPs, n=154 NPPs; average survey completion time, 12 minutes; response rate, 18% [additional information regarding response rate calculations provided in the online supplement ^{(306.2KB, pdf)} ]). Detailed HCP demographics are shown in Table 2. HCPs reported that COPD severity in their patients was evenly distributed among mild, moderate, severe, and very severe disease (24%, 32%, 27%, and 17%, respectively). The patient survey was completed by 505 patients (average survey completion time, 16 minutes; response rate, 65% [additional information regarding response rate calculations provided in the online supplement ^{(306.2KB, pdf)} ]). Six surveys had a completion time significantly lower than the average and were excluded, resulting in 499 eligible surveys. Respondents were predominantly white, female, aged 55 to 74 years, and with some level of college education. Detailed patient characteristics are shown in Table 3.

Inhaler Device Selection and Assessment

When selecting maintenance treatment for patients with stable COPD, the majority of HCPs placed greater importance on medication class over device type (Figure 1a). Furthermore, in newly diagnosed patients with either stable or post-exacerbation COPD, only about one-third of all HCPs considered the inhalation device to be highly important when prescribing medication (Figure 1b and 1c).

Approximately one-half of surveyed HCPs reported always or frequently considering the burden of learning a new device technique when prescribing multiple medications for COPD. In addition, when considering barriers to COPD management, the concern that medication was not getting into a patient’s lungs because of poor device use was moderate among all HCPs (3.3 and 3.5 [5-point Likert-type scale] for mild to moderate and severe to very severe disease, respectively). Furthermore, when selecting a medication for newly diagnosed patients with COPD, only 45% of all HCPs assessed the ability to use the device in every patient. A statistically significant difference was found by HCP type (ꭓ² (2) = 320.7, p=0.0001); post hoc tests showed PUDs (52%) and NPPs (49%) were significantly more likely to assess a patient’s ability to use a device in every case compared to PCPs (32%) (PUDs versus PCP p=0.001; NPP versus PCP p=0.012) (Figure 2).

Changing Medications or Devices

The majority of HCPs (87%) reported that they were much more likely to change or add medications than to switch to a different inhalation device with the same medication in patients with established COPD experiencing frequent exacerbations. Hospitalists (46%) and PUDs (41%) were reported to be the most likely to determine which medications and devices a patient is prescribed upon hospital discharge. The majority of PCPs and NPPs maintained the treatment plan provided upon discharge, whereas 50% of PUDs devised a new one (Figure 3).

Educating Patients on Device Use

Although fewer than half of all HCPs assessed the ability to use the device in every patient with newly diagnosed COPD as previously stated, the majority (88%) reported educating their patients with COPD on proper inhaler device use. Individualized one-on-one training was reported by most HCPs overall (81%) but less often by PCPs (67%). Other common educational methods were the use of placebo devices (43%), printed materials (43%), and training on a patient’s actual device (40%). Using a 5-point Likert-type scale, HCPs were most likely to provide education on the correct use of a device (4.5), proper breathing technique (4.4), and the correct assembly of a device (4.2). Proper storage of a device (3.8), procedures for cleaning a device (3.7), and making minor repairs to a device (2.7) received less emphasis.

Patient-Reported Medication Adherence

More than three-quarters of patients reported taking their COPD medication all (55%) or most (26%) of the time. However, using MARS-5 scores suggested that approximately only one-half (51%) of patients had a high level of adherence to their COPD medication, 36% had a medium level, and 13% had a low level. Patients whose COPD was managed by a PUD were more likely to report high medication adherence than patients managed by a PCP (57% versus 47%). Patients with low adherence generally reported less understanding of their illness, less understanding of and satisfaction with their COPD management, and greater confusion and apprehension about their prescription medications. Although patients generally did not find it physically difficult to handle their medications or devices, those with low adherence were more likely to report trouble manipulating their medications or devices. Most patients (79%) reported experiencing 1 or more physical issues that could impact their ability to correctly manipulate an inhaler device, and 58% identified 2 or 3 impediments. Patients reported arthritis, difficulty with fine motor activities, and poor eyesight as the most common potential impediments to device use (Table 4).

Patient Device Prioritization and Use

Patients were much more likely to worry about the effectiveness of their COPD medication (49% some, most, or all of the time) than the proper use of their device (19% some, most, or all of the time). Sixty-four percent of patients were never concerned about their device technique (Figure 4). Nearly three-quarters (72%) of patients reported using an MDI (Figure 5), with one-third (33%) reporting that they preferred an MDI and another 35% reporting no device preference. Patients with more severe symptoms (mMRC score, ≥2) were more likely to report using an SVN (49%) than a DPI (39%), MDI (38%), or SMI (36%).

When surveyed about the different inhaler devices used, the majority of patients reported that their inhalation device, regardless of type, was very simple to use, assemble, and operate. However, a substantially greater percentage of patients who used SVNs (82%) were “very confident about medication delivery” compared to patients who used DPIs (51%), MDIs (57%), or SMIs (62%). Most patients (61%-69%) believed that they used their device correctly all the time, with patients who used SVNs being most confident.

Only 52% of patients reported changes in treatment to access an easier-to-use device (Figure 6); this was more common in patients managed by PUDs compared to those managed by PCPs (63% versus 42%; p=0.001). Patients reported COPD symptoms and exacerbations as the most frequent reasons (57%) for treatment changes. Patients who reported low adherence were more likely to undergo treatment changes due to “device issues” than patients with high adherence (13% versus 3%). Most patients reported undergoing some type of device training, although training was not uniform or complete (Table 5). Patients expressing higher satisfaction with their COPD management were more likely to have undergone training, and PUDs were more likely to have delivered extensive device training than PCPs.

Discussion

Our findings unveil important HCP and patient perspectives about the role of inhalation devices in COPD treatment. Of note, both groups place more importance on the actual medication than its delivery device. Furthermore, concerns about proper device use are limited, with the ability to use inhalation devices not routinely assessed and inconsistent education given to ensure proper device use. Our HCP survey further demonstrates that device type is considered of limited importance when prescribing medication for newly diagnosed patients with stable or unstable COPD. Moreover, HCPs did not uniformly view poor device technique as a significant barrier to optimal COPD management, with fewer than half reporting that they assessed device technique in every newly diagnosed patient. This testing appeared to occur even less often among PCPs.

Consistent with our findings with HCPs, patients with COPD were relatively unconcerned with proper device technique, regardless of their COPD severity. Treatment changes were typically triggered by symptoms and exacerbations rather than poor device technique. Two factors, low-medication adherence and management by a PUD, were associated with a higher likelihood of changing treatment to access an easier-to-use device. Despite limited concerns about device technique, potential barriers to optimal device use were relatively common among patients. Patients with the lowest medication adherence scores were more likely to cite physical difficulties when handling their medications or devices.

Interestingly, although most HCPs did not report consistently checking device technique in newly diagnosed patients, the majority reported providing individualized one-on-one training, although less often by PCPs. Furthermore, patients did not identify education as a significant impediment to proper device use, but most patients reported undergoing some type of device training, particularly if treated by PUDs. However, the educational experiences reported by patients were well short of universal, in relative contradistinction to the high educational efforts reported by HCPs. Greater efforts toward device education were associated with patients’ higher satisfaction with their COPD management, suggesting the benefits of education extend beyond a patient’s comfort level with device use. It is worth noting that resources are available to assist HCPs with device training from the COPD Foundation (https://www.copdfoundation.org/Learn-More/For-Patients-Caregivers/Educational-Video-Series/Inhaler-Training-Videos.aspx) and the American College of Chest Physicians (https://www.chestnet.org/Store/Products/Standard-Products/eLearning/Respiratory-Devices-to-Manage-Obstructive-Lung-Disease).

Our findings support the work of other investigators who have urged for improved educational efforts to ensure the proper use of inhalation devices for people with chronic respiratory diseases, including COPD.^6,7,17 Improper use of inhalers has been cited as a major factor in worsening outcomes for people with respiratory diseases,⁵ with up to 68% of patients with respiratory diseases (including COPD) not using their MDIs or DPIs appropriately.¹⁷ Inhaler misuse has been associated with a lack of device instruction by HCPs, and up to 67% of HCPs—including physicians, nurses, and respiratory care practitioners—reportedly cannot describe or perform basic steps of inhaler use.¹⁸ Poor inhalation device technique also has been linked to poorer clinical outcomes^5,19 and disease control, as well as increased costs.²⁰

Notably, our survey responses suggest that HCPs overestimate the extent and effectiveness of the device training they provide to their patients, which may limit the importance HCPs place on their own education around inhalation devices. It is of paramount importance that HCPs recognize the necessity of such professional education to be receptive to it. Education must also address HCP time constraints, which have been cited as a significant barrier to effective patient education on inhaler use.¹⁷ Ultimately, we see this type of professional education coordinating with patient-directed educational efforts to further promote the importance of proper device selection and use in COPD management.

Our study has several limitations, the most notable being the inherent selection bias in survey-based analyses. Additionally, the overall physician response rate was very low (18%), which raises the possibility of nonresponse bias. Physician results could have been different had a greater proportion of invited physicians participated in the survey. Participants opted into the survey, so there is the possibility for self-selection of more motivated HCPs and patients. The sample size for NPPs was small and not evenly distributed among specialties, making subgroup analysis difficult. The study was performed in the United States; thus, we are unable to generalize our findings to other countries where access to care and inhalation device selection may be governed by other factors. Finally, a 2014 study by Tommelein et al demonstrated that MARS-5 was not the most robust instrument for identifying nonadherence to inhalation medication in COPD.¹⁵ This was recognized at the study outset; however, it was chosen because it was easy for patients to self-administer and allowed for a general segmentation of the patient population by ranges of adherence scores.

Conclusions

In summary, our study uncovers several gaps in HCP and patient understanding of the role of inhalation devices in COPD management. It also highlights potential unmet needs and opportunities for future interventions to coordinate professional and patient-directed education to further promote proper device selection and use in COPD management.

Abbreviations

chronic obstructive pulmonary disease, COPD; Delivery Makes a Difference, DMaD; health care provider, HCP; metered-dose inhaler, MDI; dry-powder inhaler, DPI; soft mist inhaler, SMI; small volume nebulizer, SVN; pulmonologist, PUD; primary care physician, PCP; non-physician provider, NPP; Medication Adherence Report Scale, MARS-5; modified Medical Research Council Dyspnea Scale, mMRC

Funding Statement

Sunovion Pharmaceuticals Inc., provided funding for the implementation of the survey and medical writing but did not influence the design, conduct of the study, or content of the submitted manuscript.